Blinatumomab-associated vasculitis

Liau, MeiQi May; Long, Valencia; Huang, Jingxiang; Jaffar, Huma

doi:10.1016/j.jdcr.2017.01.017

Cited by 6 publications

(6 citation statements)

References 4 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Histopathologic features may include a dermal hypersensitivity reaction with perivascular lymphocytic inflammation (Figure 5). Another study showed tender erythematous nodules on the dorsum of the foot following intravenous administration of blinatumomab 207 . Skin biopsy showed medium‐vessel vasculitic changes and histiocytic infiltrates with intermittent CD3 + T‐cells 207 …”

Section: Resultsmentioning

confidence: 99%

“…Another study showed tender erythematous nodules on the dorsum of the foot following intravenous administration of blinatumomab 207 . Skin biopsy showed medium‐vessel vasculitic changes and histiocytic infiltrates with intermittent CD3 + T‐cells 207 …”

Section: Resultsmentioning

confidence: 99%

“…Another study showed tender erythematous nodules on the dorsum of the foot following intravenous administration of blinatumomab. 207 Skin biopsy showed medium-vessel vasculitic changes and histiocytic infiltrates with intermittent CD3 + T-cells. 207 CD19 is also the target for the mAbs denintuzumab mafodotin, loncastuximab tesirine, and tafasitamab-cxix in the treatment of non-Hodgkin lymphoma.…”

Section: Cd19mentioning

confidence: 99%

See 2 more Smart Citations

The diverse landscape of dermatologic toxicities of non‐immune checkpoint inhibitor monoclonal antibody‐based cancer therapy

et al. 2022

View full text Add to dashboard Cite

Background Since their first approval 25 years ago, monoclonal antibodies (mAbs) have become important targeted cancer therapeutics. However, dermatologic toxicities associated with non−immune checkpoint inhibitor (non‐ICI) mAbs may complicate the course of cancer treatment. Data on the incidence and types of these reactions are limited. Methods A comprehensive review was conducted on dermatologic toxicities associated with different classes of non‐ICI mAbs approved for treatment of solid tumors and hematologic malignancies. The review included prospective Phase 1, 2, and 3 clinical trials; retrospective literature reviews; systematic reviews/meta‐analyses; and case series/reports. Results Dermatologic toxicities were associated with several types of non‐ICI mAbs. Inflammatory reactions were the most common dermatologic toxicities, manifesting as maculopapular, urticarial, papulopustular/acneiform, and lichenoid/interface cutaneous adverse events (cAEs) with non‐ICI mAbs. Immunobullous reactions were rare and a subset of non‐ICI mAbs were associated with the development of vitiligo cAEs. Conclusion Dermatologic toxicities of non‐ICI mAbs are diverse and mostly limited to inflammatory reactions. Awareness of the spectrum of the histopathologic patterns of cAE from non‐ICI mAbs therapy is critical in the era of oncodermatology and oncodermatopathology.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Cd19mentioning

confidence: 99%

See 1 more Smart Citation

The diverse landscape of dermatologic toxicities of non‐immune checkpoint inhibitor monoclonal antibody‐based cancer therapy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Development of mid‐vessel vasculitis in the feet at D15 of the first course. Blinatumomab was stopped and then restarted 1 week later at lower doses 91 …”

Section: Resultsmentioning

confidence: 99%

“…Blinatumomab was stopped and then restarted 1 week later at lower doses. 91 There are cases of patients who had disabling symptoms due to the disease that resolved after administration of blinatumomab. For example, one case of decreased visual acuity due to leukaemic cell infiltration of the optic nerves 92 improved on blinatumomab.…”

Section: Hypogammaglobulinemiamentioning

confidence: 99%

The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials

Mocquot

Mossazadeh

Lapierre

et al. 2022

Clinical Pharmacy Therapeu

View full text Add to dashboard Cite

What is known and objective Bispecific drugs (BDs) belong to the family of immunotherapies along with checkpoint inhibitors and CAR‐T cells. In the field of oncology, BDs are designed to simultaneously bind a tumour antigen on the one side and an antigen present on the surface of effector cells on the other. This review summarizes the information available to date on the first marketed BiTE‐format bispecific antibody, blinatumomab BLINCYTO® in acute lymphoblastic leukaemia. Methods A literature search was conducted in the PubMed database by including studies published in English using the term blinatumomab. Furthermore, bibliographies of selected references were also evaluated for relevant articles. Clinical trial (CT) data were retrieved from clinicaltrials.gov (ongoing trials, adverse events [AEs]) and global pharmacovigilance data were retrieved from VigiBase®. Results and discussion Blinatumomab is a fusion protein which consists of two single‐chain variable fragments arranged in tandem: the first binds the CD19 surface antigen of all B cells and the second targets the CD3 antigen of T cells. Binding of blinatumomab to B and T cells induces apoptosis of B cells after secretion of granzymes and perforins by T cells. T‐cell activation results in secretion of pro‐inflammatory cytokines and upregulation of activation markers and adhesion molecules on the surface of T cells. The major CTs that led to an indication show increased overall survival with blinatumomab with better efficacy in patients in haematological remission with minimal residual disease ≥10−3. The major AEs are cytokine release syndrome, neurotoxicity and hypogammaglobulinemia. The three most frequent system organ classes in CTs are haematological, gastrointestinal and general disorders. These results are also found in VigiBase® but neurological disorders and infections appear more frequently in real life. What is new and conclusion This review summarizes the current knowledge of blinatumomab in the literature. The subject of many CTs is to improve the route of administration and expand the indications for treatment.

show abstract

Blinatumomab

2017

Reactions Weekly

View full text Add to dashboard Cite

Blinatumomab-associated vasculitis

Cited by 6 publications

References 4 publications

The diverse landscape of dermatologic toxicities of non‐immune checkpoint inhibitor monoclonal antibody‐based cancer therapy

The diverse landscape of dermatologic toxicities of non‐immune checkpoint inhibitor monoclonal antibody‐based cancer therapy

The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials

Blinatumomab

Contact Info

Product

Resources

About